Literature DB >> 17352936

Selective degeneration in YAC mouse models of Huntington disease.

Jeremy M Van Raamsdonk1, Simon C Warby, Michael R Hayden.   

Abstract

Huntington disease (HD) is one of at least nine polyglutamine disorders caused by a CAG expansion in the coding region of a disease-causing gene. These disorders are characterized by selective degeneration of different regions of the brain, which is not explained by the expression pattern of the mutant protein. In HD, degeneration primarily occurs in the striatum and cortex. To examine the mechanisms responsible for the selective neuronal loss in HD, we have generated yeast artificial chromosome (YAC) transgenic models of HD that express full length mutant huntingtin (htt) from a YAC. These mice have appropriate tissue-specific and temporal expression of mutant htt and accordingly recapitulate the motor deficits, cognitive impairment and selective degeneration of HD. As in human patients, mutant htt expression is not increased in the affected regions of the brain. In contrast, detection of mutant htt in the nucleus is earliest and greatest in the striatum, the region most affected in HD, suggesting that selective nuclear localization of mutant htt may contribute to the region specific atrophy in these mice. Selective phosphorylation of mutant htt on serine 421 may also contribute, as phosphorylation of mutant htt reduces its toxicity and is decreased in the striatum compared to other regions of the brain. Finally, the fact that mutant htt expression increases the susceptibility of striatal neurons to excitotoxicity but not neurons from the cerebellum, suggests that altered sensitization to excitotoxic death may also contribute to selective degeneration in YAC mice. Overall, YAC mice recapitulate the region specific damage that occurs in HD and provide a suitable model for examining the mechanisms underlying of selective degeneration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17352936     DOI: 10.1016/j.brainresbull.2006.10.018

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  22 in total

1.  Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background.

Authors:  Melissa K Strong; Amber L Southwell; Jennifer M Yonan; Michael R Hayden; Grant R Macgregor; Leslie M Thompson; Oswald Steward
Journal:  J Huntingtons Dis       Date:  2012

Review 2.  Mitochondrial medicine for aging and neurodegenerative diseases.

Authors:  P Hemachandra Reddy
Journal:  Neuromolecular Med       Date:  2008-06-20       Impact factor: 3.843

Review 3.  Animal and model systems for studying cystic fibrosis.

Authors:  Bradley H Rosen; Marc Chanson; Lara R Gawenis; Jinghua Liu; Aderonke Sofoluwe; Alice Zoso; John F Engelhardt
Journal:  J Cyst Fibros       Date:  2017-09-19       Impact factor: 5.482

Review 4.  Antioxidants in central nervous system diseases: preclinical promise and translational challenges.

Authors:  Chandrashekhar D Kamat; Sunyana Gadal; Molina Mhatre; Kelly S Williamson; Quentin N Pye; Kenneth Hensley
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

5.  Probing the metabolic aberrations underlying mutant huntingtin toxicity in yeast and assessing their degree of preservation in humans and mice.

Authors:  P Matthew Joyner; Ronni M Matheke; Lindsey M Smith; Robert H Cichewicz
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

Review 6.  Mouse models of Huntington's disease and methodological considerations for therapeutic trials.

Authors:  Robert J Ferrante
Journal:  Biochim Biophys Acta       Date:  2009-04-10

7.  Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.

Authors:  Hyemyung Seo; Woori Kim; Ole Isacson
Journal:  Hum Mol Genet       Date:  2008-07-17       Impact factor: 6.150

8.  Partial ablation of mu-opioid receptor rich striosomes produces deficits on a motor-skill learning task.

Authors:  C Lawhorn; D M Smith; L L Brown
Journal:  Neuroscience       Date:  2009-05-20       Impact factor: 3.590

9.  Disruption of Purkinje cell function prior to huntingtin accumulation and cell loss in an animal model of Huntington disease.

Authors:  S E Dougherty; J L Reeves; E K Lucas; K L Gamble; M Lesort; R M Cowell
Journal:  Exp Neurol       Date:  2012-05-02       Impact factor: 5.330

Review 10.  Magnetic resonance imaging of Huntington's disease: preparing for clinical trials.

Authors:  S Klöppel; S M Henley; N Z Hobbs; R C Wolf; J Kassubek; S J Tabrizi; R S J Frackowiak
Journal:  Neuroscience       Date:  2009-01-29       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.